Cot
Amnestic Disorder
Evon Medics LLCUNKNOWNPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
7 Active assets in the Amnestic Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Madopar Peking University Third Hospital | Phase 4 | BB |
Celecoxib University of California, Los Angeles | Phase 3 | B |
Ladostigil Hemitartrate Avraham Pharmaceuticals Ltd | Phase 2 | B |
Metformin University of Pennsylvania | Phase 2 | B |
Atomoxetine Icahn School of Medicine at Mount Sinai | Phase 2 | B |
View all 13 →
Same molecule, other indications
Cot is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →